Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has entered into a definitive merger agreement with Pharma Two B Ltd., an Israeli company developing a Parkinson's Disease drug. The merger is valued at approximately $58.5 million, and the combined company will operate under the 'Pharma Two B' name. Pharma Two B will file a registration statement with the SEC and apply to list its shares on Nasdaq under the ticker symbol 'PHTB'. Hepion also announced a $2.9 million private placement of non-convertible senior notes, while Pharma Two B secured an $11.5 million private placement of shares and warrants. HEPA stock is up 1.96% at $1.04 in premarket trading.